Jacc: Cardiooncology最新文献

{"title":"Shared Mechanisms in Cancer and Cardiovascular Disease: S100A8/9 and the NLRP3 Inflammasome","authors":"Sophie Van Linthout PhD","doi":"10.1016/j.jaccao.2024.10.010","DOIUrl":"10.1016/j.jaccao.2024.10.010","url":null,"abstract":"<div><div>Inflammation and a dysregulated immune system are common denominators in cancer and cardiovascular disease (CVD). The Canakinumab Anti-Inflammatory Thrombosis Outcome Study (CANTOS) highlighted the convergence of interleukin (IL)-1β biology in cancer and CVD, and the potential of anti–IL-1β drugs for the treatment of both disease entities. Accumulating evidence further supports the role of the innate immunity members and IL-1β activators, S100A8/9 and the NLRP3 inflammasome, in both cancer and CVD. This review outlines the common involvement of S100A8/9 and the NLRP3 inflammasome, in cancer and CVD. Specifically, their time-, cell-, and context-dependent actions and hereto-related dichotomous role in different cancers and CVD are addressed, highlighting the need for further insights to allow tailored therapies.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 5","pages":"Pages 501-513"},"PeriodicalIF":12.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood Pressure Lowering and Risk of Cancer","authors":"Milad Nazarzadeh DPhil ,&nbsp;Emma Copland MSc ,&nbsp;Karl Smith Byrne DPhil ,&nbsp;Dexter Canoy MD ,&nbsp;Zeinab Bidel MSc ,&nbsp;Mark Woodward PhD ,&nbsp;Qianqian Yang MSc ,&nbsp;James McKay PhD ,&nbsp;Anders Mälarstig PhD ,&nbsp;Åsa K. Hedman PhD ,&nbsp;John Chalmers MD ,&nbsp;Koon K. Teo MD ,&nbsp;Carl J. Pepine MD ,&nbsp;Barry R. Davis MD ,&nbsp;Sverre E. Kjeldsen MD ,&nbsp;Johan Sundström MD ,&nbsp;Kazem Rahimi DM ,&nbsp;Blood Pressure Lowering Treatment Trialists’ Collaboration","doi":"10.1016/j.jaccao.2025.03.005","DOIUrl":"10.1016/j.jaccao.2025.03.005","url":null,"abstract":"<div><h3>Background</h3><div>Pharmacologic blood pressure (BP) lowering is typically a lifelong treatment, and both clinicians and patients may have concerns about the long-term use of antihypertensive agents and the risk for cancer. However, evidence from randomized controlled trials (RCTs) regarding the effect of long-term pharmacologic BP lowering on the risk for new-onset cancer is limited, with most knowledge derived from observational studies.</div></div><div><h3>Objectives</h3><div>The aim of this study was to assess whether long-term BP lowering affects the risk for new-onset cancer, cause-specific cancer death, and selected site-specific cancers.</div></div><div><h3>Methods</h3><div>Individual-level data from 42 RCTs were pooled using a one-stage individual participant data meta-analysis. The primary outcome was incident cancer of all types, and secondary outcomes were cause-specific cancer death and selected site-specific cancers. Prespecified subgroup analyses were conducted to assess the heterogeneity of the BP-lowering effect by baseline variables and over follow-up time. Cox proportional hazards regression, stratified by trial, was used for the statistical analysis. For site-specific cancers, analyses were complemented with Mendelian randomization, using naturally randomized genetic variants associated with BP lowering to mimic the design of a long-term RCT.</div></div><div><h3>Results</h3><div>Data from 314,016 randomly allocated participants without known cancer at baseline were analyzed. Over a median follow-up of 4 years (Q1-Q3: 3-5 years), 17,954 participants (5.7%) developed cancer, and 4,878 (1.5%) died of cancer. In the individual participant data meta-analysis, no associations were found between reductions in systolic or diastolic BP and cancer risk (HR per 5 mm Hg reduction in systolic BP: 1.03 [95% CI: 0.99-1.06]; HR per 3 mm Hg reduction in diastolic BP: 1.03 [95% CI: 0.98-1.07]). No changes in relative risk for incident cancer were observed over follow-up time, nor was there evidence of heterogeneity in treatment effects across baseline subgroups. No effect on cause-specific cancer death was found. For site-specific cancers, no evidence of an effect was observed, except a possible link with lung cancer risk (HR for systolic BP reduction: 1.17; 99.5% CI: 1.02-1.32). Mendelian randomization studies showed no association between systolic or diastolic BP reduction and site-specific cancers, including overall lung cancer and its subtypes.</div></div><div><h3>Conclusions</h3><div>Randomized data analysis provided no evidence to indicate that pharmacologic BP lowering has a substantial impact, either increasing or decreasing, on the risk for incident cancer, cause-specific cancer death, or selected site-specific cancers.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 5","pages":"Pages 609-623"},"PeriodicalIF":12.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mind the Translational Gap","authors":"Caitlin Bell MD","doi":"10.1016/j.jaccao.2025.04.005","DOIUrl":"10.1016/j.jaccao.2025.04.005","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 5","pages":"Pages 590-592"},"PeriodicalIF":12.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144162949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Hematologic Malignancies in Patients With Acute Myocardial Infarction","authors":"Seug Yun Yoon MD ,&nbsp;Mina Kim MS ,&nbsp;Hoseob Kim MPH ,&nbsp;Duk Won Bang MD, PhD ,&nbsp;Byoung-Won Park MD, PhD ,&nbsp;Sun Young Jeong MD ,&nbsp;Min-Young Lee MD, PhD ,&nbsp;Kyoung Ha Kim MD, PhD ,&nbsp;Namsu Lee MD, PhD ,&nbsp;Jong-Ho Won MD, PhD ,&nbsp;Inki Moon MD, PhD ,&nbsp;Jon Suh MD, PhD ,&nbsp;Seong Soon Kwon MD, PhD","doi":"10.1016/j.jaccao.2025.04.003","DOIUrl":"10.1016/j.jaccao.2025.04.003","url":null,"abstract":"<div><h3>Background</h3><div>Acute myocardial infarction (AMI) and cancer are leading causes of death worldwide. However, the relationship between AMI and hematologic malignancies remains unclear.</div></div><div><h3>Objectives</h3><div>The authors aimed to investigate the association between AMI and the subsequent risk of incident hematologic malignancies.</div></div><div><h3>Methods</h3><div>This retrospective cohort study included 103,686 patients with AMI and no history of hematologic malignancies, and 103,686 age- and sex-matched individuals with no history of AMI or hematologic malignancies, diagnosed between January 1, 2003, and December 31, 2021. Data were obtained from the Korean National Health Insurance claims database. We compared the cumulative incidence of hematologic malignancies between groups using Gray’s method. HRs and 95% CIs were calculated using Gray’s competing risk regression model, with death treated as a competing risk.</div></div><div><h3>Results</h3><div>During follow-up (AMI, 7.9 years [Q1-Q3: 5.2-11.4 years]; control group, 17.8 years [Q1-Q3: 14.8–17.9 years]), 1,043 and 1,479 individuals in the AMI and control groups, respectively, were newly diagnosed with hematologic malignancies (incidence rate per 1,000 person-years: 1.21 vs 0.93). Competing risk analysis revealed that the AMI group had a higher risk of hematologic malignancy than the control group (HR: 1.49; 95% CI: 1.31-1.69). Findings were consistent in sensitivity and standardized incidence ratio analyses.</div></div><div><h3>Conclusions</h3><div>Patients with AMI had a higher risk of hematologic malignancies than those without AMI. These findings suggest an association between AMI and hematologic malignancies, and underscore the importance of considering hematologic malignancy development in patients with AMI.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 5","pages":"Pages 580-589"},"PeriodicalIF":12.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144162953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Development in Atherosclerotic Cardiovascular Disease","authors":"Jessie M. Dalman BA ,&nbsp;Kathryn J. Moore PhD","doi":"10.1016/j.jaccao.2025.05.016","DOIUrl":"10.1016/j.jaccao.2025.05.016","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 5","pages":"Pages 514-517"},"PeriodicalIF":12.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144865124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral Ischemia Fuels Breast Cancer Via Myeloid-Skewed Hematopoiesis","authors":"Pilar Martín PhD","doi":"10.1016/j.jaccao.2025.07.002","DOIUrl":"10.1016/j.jaccao.2025.07.002","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 5","pages":"Pages 578-579"},"PeriodicalIF":12.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144867404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer-Related Immune Therapies","authors":"Kapka Miteva PhD ,&nbsp;Markus S. Anker MD ,&nbsp;Henry Fechner DVM ,&nbsp;Lorenz Lehmann MD ,&nbsp;Sophie Van Linthout PhD","doi":"10.1016/j.jaccao.2025.06.008","DOIUrl":"10.1016/j.jaccao.2025.06.008","url":null,"abstract":"<div><div>Immune-based therapies—including immune checkpoint inhibitors, bispecific T cell engagers, chimeric antigen receptor T cells, and tumor-infiltrating lymphocytes— not only have transformed cancer treatment, but also have introduced significant cardiovascular complications, posing new challenges for cardio-oncology. Growing recognition of cardiovascular immune-related adverse events has spurred research into the immune–cardiovascular interface, particularly dysregulated signaling, T cell overactivation, and cytokine release. This review synthesizes recent insights into the role of immune checkpoints in cardiovascular disease, the mechanisms of immune checkpoint inhibitor– and T cell–induced cardiotoxicity, and the therapeutic potential of immune checkpoint modulation and chimeric antigen receptor T cell therapy in cardiovascular applications.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 5","pages":"Pages 523-537"},"PeriodicalIF":12.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144865126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular Risk Assessment in Patients With Kidney Cancer","authors":"Kriti Mittal MD, MS ,&nbsp;Jenica N. Upshaw MD, MSc","doi":"10.1016/j.jaccao.2025.07.004","DOIUrl":"10.1016/j.jaccao.2025.07.004","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 5","pages":"Pages 641-643"},"PeriodicalIF":12.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144865110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Growing Intersection Between Cancer and Cardiovascular Disease","authors":"Bonnie Ky MD, MSCE, FACC (Editor-in-Chief, JACC: CardioOncology)","doi":"10.1016/j.jaccao.2025.07.006","DOIUrl":"10.1016/j.jaccao.2025.07.006","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 5","pages":"Pages 646-647"},"PeriodicalIF":12.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144865118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer and Cardiovascular Disease","authors":"Laith Alhuneafat MD ,&nbsp;Avirup Guha MD, MPH ,&nbsp;Anne Blaes MD, MS ,&nbsp;Suma H. Konety MD, MS","doi":"10.1016/j.jaccao.2025.07.001","DOIUrl":"10.1016/j.jaccao.2025.07.001","url":null,"abstract":"<div><div>Cancer and cardiovascular disease (CVD) remain the leading causes of morbidity and mortality worldwide, with emerging evidence highlighting their complex and bidirectional interplay. Shared risk factors, including aging, systemic inflammation, metabolic dysregulation, and lifestyle behaviors, can contribute to their co-occurrence while underlying biological mechanisms such as oxidative stress, chronic inflammation, and clonal hematopoiesis further reinforce their connection. These mechanisms drive pathophysiological changes contributing to disease progression, increasing susceptibility to both conditions. This review explores the epidemiology, overlapping biological pathways, and risk factors linking cancer and CVD, emphasizing key mechanisms such as epigenetic modifications, immune system dysregulation, and cellular senescence. Future research should aim to identify biomarkers, refine risk models, and develop targeted strategies to mitigate disease burden and improve outcomes.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 5","pages":"Pages 453-469"},"PeriodicalIF":12.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144865121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}